Search Results
Article Topics
Your search for all items matches 910 pages
Showing 151 - 200FDA Grants Breakthrough Therapy Designation to LOXO-292 for Treatment of Lung and Thyroid Cancers
The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to LOXO-292, a selective RET inhibitor, for: the treatment of patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) who require systemic therapy and have had...
CNS Activity of First-Line Osimertinib in EGFR-Mutant Advanced NSCLC
In a subgroup analysis of the phase III FLAURA trial reported in the Journal of Clinical Oncology, Reungwetwattana et al found evidence of greater central nervous system (CNS) activity of osimertinib (Tagrisso) vs standard EGFR tyrosine kinase inhibitors in patients with previously untreated...
Tumor Mutation Burden and Prognosis in Resected NSCLC
In a study reported in the Journal of Clinical Oncology, Devarakonda et al found that high nonsynonymous tumor mutation burden was associated with improved outcomes in patients undergoing resection for non–small cell lung cancer (NSCLC). Study Details The study (Lung Adjuvant Cisplatin...
FDA Approves cobas EGFR Mutation Test v2 as Companion Diagnostic With Gefitinib in First-Line Treatment of NSCLC
The U.S. Food and Drug Administration (FDA) recently approved the cobas EGFR Mutation Test v2 as a companion diagnostic test with gefitinib (Iressa) for the first-line treatment of patients with non–small cell lung cancer (NSCLC). A companion diagnostic test provides information that is...
Baseline Steroids and Efficacy of PD-1/PD-L1 Inhibitors in NSCLC
In a study reported in the Journal of Clinical Oncology, Arbour et al found that baseline treatment with corticosteroids was associated with poorer efficacy of programmed cell death protein 1 (PD-1) or programmed death cell ligand 1 (PD-L1) inhibitors in patients with non–small cell lung...
Active Surveillance of Lung Subsolid Nodules May Reduce Unnecessary Surgery and Overtreatment
Subsolid nodules can be considered a biomarker of lung cancer risk, and should be managed with long-term active surveillance. Conservative management of these nodules may reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from...
FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC
Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with pemetrexed (Alimta) and platinum as first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer with no EGFR or ALK genomic tumor aberrations. Pembrolizumab...
FDA Approves Nivolumab for Certain Patients With Previously Treated Small Cell Lung Cancer
Today, nivolumab (Opdivo) received approval from the U.S. Food and Drug Administration (FDA) for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. Approval for this indication has been...
Small Study Looks at Physician-Patient Discussions About Lung Cancer Screening
National guidelines advise doctors to discuss the benefits and harms of lung cancer screening with high-risk patients. A small study (n = 14) by researchers from the University of North Carolina Lineberger Comprehensive Cancer Center reported there is a gap between what guidelines...
Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting
In a study reported in JAMA, Presley et al found that use of broad-based genomic sequencing vs routine testing for EGFR mutations or ALK rearrangements alone directed treatment in a minority of patients with advanced non–small cell lung cancer (NSCLC) in the community oncology setting and was ...
CNS Activity of EGFR Tyrosine Kinase Inhibitor in T790M-Positive Advanced NSCLC
In a planned subgroup analysis of the phase III AURA3 trial reported in the Journal of Clinical Oncology, Wu et al found that the third-generation EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) produced higher central nervous system (CNS) response rates vs platinum plus pemetrexed (Alimta)...
Lung Cancer Screening Guidelines May Be Inadequate for High-Risk Minorities
Data from a lung cancer screening program at the University of Illinois at Chicago (UIC) provides evidence that national lung cancer screening guidelines, which were developed based on the National Lung Screening Trial (NLST) in 2011 and recommend screening based on age and smoking history, may be...
Osimertinib Resistance Mechanisms in EGFR T790M–Positive NSCLC
In a study reported in JAMA Oncology, Oxnard et al found early resistance and a number of competing resistance mechanisms in acquired osimertinib (Tagrisso) resistance associated with loss of the T790M mutation conferring resistance to prior EGFR tyrosine kinase inhibitor (TKI) treatment in...
Lung Cancer Mortality Among Women Projected to Increase by 43% Worldwide by 2030
According to a report by the International Agency for Research on Cancer, cancer is among the leading causes of morbidity and mortality worldwide, with an estimated incidence of 14 million new cases of the disease and 8.2 million cancer deaths in 2012. A study analyzing breast and female lung...
‘Super-Resolution’ MRI May Help Plan Radiotherapy Treatment in Lung Cancer
Physicists from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust combined standard two-dimensional magnetic resonance imaging (MRI) images of the chests of healthy volunteers to create 'super-resolution' videos, showing the lungs expanding and contracting. The...
Forum of International Respiratory Societies Issues Statement on World Lung Cancer Day
On World Lung Cancer Day (August 1), the members of the Forum of International Respiratory Societies (FIRS) commemorate, celebrate, and support those impacted by lung cancer. FIRS continues to support the grassroots efforts of the lung cancer community to raise awareness about lung cancer and its...
ALTA-1L Trial of Brigatinib vs Crizotinib in ALK-Positive Advanced NSCLC Meets Primary Endpoint
The global, randomized, phase III ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line) trial met its primary endpoint at the first prespecified interim analysis, with brigatinib (Alunbrig) demonstrating a statistically significant improvement in progression-free...
Adding Cisplatin to First-Line Treatment of Elderly Patients With Advanced NSCLC
A joint analysis of parallel phase III trials reported in the Journal of Clinical Oncology by Gridelli et al found no overall survival benefit of adding cisplatin to first-line treatment of elderly patients with advanced non–small cell lung cancer (NSCLC) without an EGFR mutation. Study...
Ado-Trastuzumab Emtansine in HER2-Mutant Lung Cancer
As reported by Li and colleagues in the Journal of Clinical Oncology, the HER2-targeted antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) showed activity in advanced HER2-mutant lung adenocarcinoma. Study Details The current report involves a cohort of patients with HER2-mutant lung...
Biomarker-Integrated Risk Model for Lung Cancer
As reported in JAMA Oncology by the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, incorporating biomarkers into a lung cancer risk prediction model may improve performance compared with risk based on age and smoking exposure alone....
IMpower 132: Atezolizumab in Combination With Pemetrexed and Platinum-Based Chemotherapy in Advanced Nonsquamous NSCLC
The phase III IMpower132 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of atezolizumab (Tecentriq) plus chemotherapy (cisplatin or carboplatin plus pemetrexed [Alimta]) reduced the risk of disease worsening or death compared to chemotherapy...
Brain Metastases in ROS1-Positive Lung Cancer and Treatment With Crizotinib
A study published by Patil et al in the Journal of Thoracic Oncology explores the occurrence and treatment of brain metastases in stage IV ROS1-positive non–small cell lung cancer. ROS1-Positive Disease vs Other Genetic Mutations Importantly, and in contrast with the findings ...
Large Disparities in Cancer Mortality Rates Found Among Different Racial/Ethnic Populations in New York State
According to the American Cancer Society, cancer is the leading cause of death for Hispanics and Asian/Pacific Islanders in the United States. However, their cancer burden is less than that of non-Hispanic whites and especially non-Hispanic blacks, who bear the most disproportionate share of the...
Geographic Differences in End-of-Life Cancer Care
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found differences in this type of cancer care across different parts of the country. The findings, published by Keating et al...
FDA Accepts sBLA for Pembrolizumab in Combination With Chemotherapy as First-Line Treatment for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) in combination with carboplatin/paclitaxel or nab-paclitaxel (Abraxane) as a first-line treatment for metastatic squamous non–small cell lung...
Addition of Veliparib to Temozolomide in Recurrent Small Cell Lung Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Pietanza et al found no benefit of adding the PARP inhibitor veliparib to temozolomide (Temodar) in recurrent platinum-sensitive or platinum-refractory small cell lung cancer. Benefit was observed with the combination in the subgroup ...
IMpower133: Atezolizumab in Combination With Chemotherapy in Previously Untreated, Extensive-Stage Small Cell Lung Cancer
The phase III IMpower133 study recently met its coprimary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis. The study demonstrated that first-line treatment with the combination of atezolizumab (Tecentriq) plus chemotherapy (carboplatin and...
FDA Accepts sBLA for First-Line Nivolumab Plus Low-Dose Ipilimumab in NSCLC With Tumor Mutational Burden ≥ 10 mut/mb
The U.S. Food and Drug Administration (FDA) recently accepted a supplemental biologics license application (sBLA) for nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the first-line treatment of advanced non–small cell lung cancer (NSCLC) in patients with a tumor mutational burden...
ERBB Mutations and Outcomes With Afatinib and Erlotinib in Squamous NSCLC
In an analysis of the LUX-Lung 8 trial in squamous non–small cell lung cancer (NSCLC) reported in JAMA Oncology, Goss et al found that outcomes among patients treated with afatinib (Gilotrif) were better for those with vs without ERBB mutations. The LUX-Lung 8 trial showed that afatinib was...
IASLC Issues Statement Paper on Liquid Biopsy for Lung Cancer
The lungs can be a difficult organ to biopsy with a needle, so the promise of identifying lung cancer through a blood-based biopsy has lung cancer experts and patients optimistic. Knowing how and when to use a liquid biopsy is critically important and led global experts at the International...
Addition of Atezolizumab to Bevacizumab and Chemotherapy in First-Line Treatment of Metastatic Nonsquamous NSCLC
As reported at the 2018 ASCO Annual Meeting and in The New England Journal of Medicine by Socinski et al, the phase III IMpower150 trial has shown that the addition of atezolizumab (Tecentriq) to bevacizumab (Avastin) plus chemotherapy significantly improved progression-free and overall survival in ...
FDA Expands Approval of Pembrolizumab for First-Line Treatment of NSCLC
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to the immune checkpoint inhibitor pembrolizumab (Keytruda) for use in combination with chemotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC). KEYNOTE-021 This...
Final Overall Survival Analysis of First-Line Crizotinib vs Chemotherapy in Advanced ALK-Positive NSCLC
As reported by Solomon and colleagues in the Journal of Clinical Oncology, the final overall survival results of the phase III PROFILE 1014 trial showed evidence of survival benefit of first-line crizotinib (Xalkori) vs chemotherapy in advanced ALK-positive non–small cell lung cancer (NSCLC). ...
Prophylactic Cranial Irradiation in Stage III NSCLC
In a Dutch phase III trial reported in the Journal of Clinical Oncology, De Ruysscher et al found that prophylactic cranial irradiation (PCI) prevented symptomatic brain metastases vs observation in patients with stage III non–small cell lung cancer (NSCLC) receiving treatment with curative...
Studies of Daratumumab in Combination With Anti–PD-L1 Agents Stopped
On May 26, Genmab A/S announced that following a planned review, the Data Monitoring Committee (DMC) has recommended that the phase Ib/II study (CALLISTO/LUC2001) of daratumumab (Darzalex) in combination with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) vs ...
Lung Cancer Incidence in Young Women vs Men in the United States
In a study reported in The New England Journal of Medicine, Jemal et al found that the incidence of lung cancer in young white and Hispanic women is now higher than that in men in the US. Study Details The study involved analysis of data from the North American Association of Central Cancer...
Characteristics and Screening of Brain Metastases in Breast Cancer and NSCLC
In a research letter published in JAMA Oncology, Cagney et al found that brain metastases were more advanced and more likely to be symptomatic in patients with breast cancer compared to patients with non–small cell lung cancer (NSCLC). Current guidelines recommend magnetic resonance imaging...
Analysis of Intracranial Response to Brigatinib in ALK-Positive NSCLC With Brain Metastases
In an analysis of two clinical trials reported in the Journal of Clinical Oncology, Camidge et al found that brigatinib (Alunbrig) produced high intracranial response rates and good intracranial progression-free survival in patients with ALK-positive non–small cell lung cancer (NSCLC) and...
2018 ASCO: Pembrolizumab Plus Chemotherapy as First-Line Treatment of Metastatic Squamous NSCLC: KEYNOTE-407 Study
Results from KEYNOTE-407, a randomized, double-blind, placebo-controlled, phase III study evaluating pembrolizumab (Keytruda) in combination with carboplatin/paclitaxel or carboplatin/nab-paclitaxel (Abraxane) as first-line treatment for metastatic squamous non–small cell lung cancer...
2018 ASCO: Dacomitinib vs Gefitinib in Advanced NSCLC With EGFR-Activating Mutations
Overall survival (OS) data from the ARCHER 1050 trial evaluating dacomitinib as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR-activating mutations compared to gefitinib showed a median OS of 34.1 months for patients...
ASCO 2018: Updated ALEX Trial Results on Alectinib in Treatment-Naive ALK Mutation–Positive NSCLC
Updated results of the global phase III ALEX trial comparing alectinib (Alecensa) with crizotinib (Xalkori) as first-line treatment against ALK-positive non–small cell lung cancer (NSCLC) show a median progression-free survival of 34.8 months in 152 patients treated with alectinib vs 10.9...
Raymond U. Osarogiagbon, MBBS, on NSCLC: A Lymph Node Collection Kit
Raymond U. Osarogiagbon, MBBS, of Baptist Cancer Center, discusses a kit used in non–small cell lung cancer resection that improves staging quality and overall survival without adding to morbidity of curative surgery (Abstract 8502).
Naoki Furuya, MD, PhD, on NSCLC: Results From the NEJ026 Study
Naoki Furuya, MD, PhD, of the St. Marianna University School of Medicine, discusses phase III study findings on a comparison of bevacizumab plus erlotinib to erlotinib in patients with untreated non–small cell lung cancer with activating EGFR mutations (Abstract 9006).
Tony Mok, MD, on NSCLC: Results From the ARCHER 1050 Trial
Tony Mok, MD, of the Chinese University of Hong Kong, discusses study findings on dacomitinib vs gefitinib for first-line treatment of advanced non–small cell lung cancer, a final overall survival analysis.
Nathan A. Pennell, MD, PhD, on NSCLC: Lowering Genetic Testing Costs
Nathan A. Pennell, MD, PhD, of the Cleveland Clinic, discusses the economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in newly diagnosed metastatic non–small cell lung cancer (Abstract 9031).
Danh Pham, MD: Lung Cancer Screening Rates Still Too Low
Danh Pham, MD, of the James Graham Brown Cancer Center, University of Louisville, discusses his findings using a registry on the low rates of screening with low-dose computed tomography, despite its potential to prevent thousands of lung cancer deaths each year (Abstract 6504).
Gilberto Lopes, MD, MBA, on NSCLC: Results From the KEYNOTE-042 Trial
Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, discusses phase III findings on pembrolizumab vs platinum-based chemotherapy as first-line treatment for advanced/metastatic non–small cell lung cancer with a PD-L1 tumor proportion score ≥ to 1%...
2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More
A large, randomized phase III trial shows that the immunotherapy pembrolizumab (Keytruda) is a more effective initial treatment than chemotherapy (the current standard of care) for the majority of patients with the most common type of lung cancer. People with advanced non–small cell lung...
Geoffrey R. Oxnard, MD, on Lung Cancer: Results From the Circulating Cancer Genome Atlas Study
Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, discusses genome-wide sequencing for early-stage lung cancer detection from plasma cell–free DNA (Abstract LBA8501).
Robert M. Jotte, MD, PhD, on NSCLC: Results From the IMpower131 Trial
Robert M. Jotte, MD, PhD, of Rocky Mountain Cancer Centers, discusses phase III study findings on atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel, as first-line therapy in advanced squamous non–small cell lung cancer (Abstract LBA9000).
